NCT04120766View on ClinicalTrials.gov

Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

September 1, 2026

Study Completion Date

November 30, 2026

Conditions
DementiaMild Cognitive Impairment
Interventions
DRUG

Nicorandil

20 mg po qd

DRUG

Placebo

Matching tablet

Trial Locations (1)

40504

University of Kentucky, Lexington

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Gregory Jicha, MD, PhD

OTHER